Martinsried, Germany, January 12, 2010 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.
KINAXO’s phosphoproteomics platform PhosphoScout® enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using state-of-the-art quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout® as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.
About KINAXO - www.kinaxo.com
KINAXO Biotechnologies is a privately-held biotechnology service company based in Munich/Martinsried, Germany.
KINAXO offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug mode-of-action analysis, cellular target profiling, target deconvolution, and drug re-positioning.
KINAXO just completed a financing round and recently announced its collaboration with Bayer Vital GmbH for biomarker development, as well as renewing its ongoing agreement with Johnson & Johnson.
